📊 IRON Key Takeaways
Is Disc Medicine, Inc. (IRON) a Good Investment?
Disc Medicine is a pre-revenue biopharmaceutical company with substantial operating losses (-$69.5M) and significant quarterly cash burn (-$62.2M), providing approximately 14 quarters of runway at current burn rates. While the balance sheet is fortress-like with $688.4M equity and minimal debt, the deteriorating EPS (-51.8% YoY) and absence of revenue or near-term profitability visibility present fundamental weakness. Success depends entirely on clinical pipeline advancement, making this a speculative biotech investment without visibility into developmental stage or regulatory catalysts.
Disc Medicine remains a pre-revenue biotechnology company with no demonstrated commercial earnings base, while operating and net losses are large and worsening. Its balance sheet is currently strong, with high liquidity, low leverage, and substantial equity capital, but the business is still defined by heavy cash burn and execution risk rather than durable operating fundamentals. Until revenue visibility, burn reduction, or clinical-to-commercial conversion improves, the fundamental profile remains weak.
Why Buy Disc Medicine, Inc. Stock? IRON Key Strengths
- Fortress balance sheet with $688.4M stockholders equity and only $61.8M liabilities
- Minimal leverage with 0.04x debt-to-equity ratio and low financial distress risk
- Substantial asset base of $750.2M suggesting significant R&D investments and IP development
- Very strong liquidity with a 21.94x current ratio and substantial cash relative to liabilities
- Low leverage, with debt/equity of just 0.04x and a modest long-term debt load
- Large equity base of $739.83M provides balance-sheet flexibility to fund development
IRON Stock Risks: Disc Medicine, Inc. Investment Risks
- No revenue generation - pre-commercial development stage with undefined monetization timeline
- Severe cash burn of $62.2M per quarter limits runway to ~14 quarters without additional capital
- Deteriorating EPS performance (-51.8% YoY) indicates accelerating losses and business challenges
- High regulatory and clinical risk inherent to pharmaceutical development; path to approval unclear
- Dependent on pipeline success with no visibility into clinical trial stage, efficacy, or regulatory status
- No revenue base, making profitability and margin quality unproven
- Large and worsening losses, with net income down 94.0% year over year and operating loss of $236.02M
- Heavy negative free cash flow of $181.33M increases dependence on external funding if burn persists
Key Metrics to Watch
- Quarterly operating cash flow trend and cash runway sustainability
- Clinical trial progress, regulatory milestones, and FDA decision outcomes
- R&D spending allocation and pipeline advancement stage
- Quarterly operating cash burn and free cash flow trend
- Any emergence of product revenue or material collaboration revenue
Disc Medicine, Inc. (IRON) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 24.00x current ratio provides a solid financial cushion.
IRON Profit Margin, ROE & Profitability Analysis
IRON vs Healthcare Sector: How Disc Medicine, Inc. Compares
How Disc Medicine, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Disc Medicine, Inc. Stock Overvalued? IRON Valuation Analysis 2026
Based on fundamental analysis, Disc Medicine, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Disc Medicine, Inc. Balance Sheet: IRON Debt, Cash & Liquidity
IRON Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Disc Medicine, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.42 indicates the company is currently unprofitable.
IRON Revenue Growth, EPS Growth & YoY Performance
Disc Medicine, Inc. Dividends, Buybacks & Capital Allocation
IRON SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Disc Medicine, Inc. (CIK: 0001816736)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IRON
What is the AI rating for IRON?
Disc Medicine, Inc. (IRON) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IRON's key strengths?
Claude: Fortress balance sheet with $688.4M stockholders equity and only $61.8M liabilities. Minimal leverage with 0.04x debt-to-equity ratio and low financial distress risk. ChatGPT: Very strong liquidity with a 21.94x current ratio and substantial cash relative to liabilities. Low leverage, with debt/equity of just 0.04x and a modest long-term debt load.
What are the risks of investing in IRON?
Claude: No revenue generation - pre-commercial development stage with undefined monetization timeline. Severe cash burn of $62.2M per quarter limits runway to ~14 quarters without additional capital. ChatGPT: No revenue base, making profitability and margin quality unproven. Large and worsening losses, with net income down 94.0% year over year and operating loss of $236.02M.
What is IRON's revenue and growth?
Disc Medicine, Inc. reported revenue of N/A.
Does IRON pay dividends?
Disc Medicine, Inc. does not currently pay dividends.
Where can I find IRON SEC filings?
Official SEC filings for Disc Medicine, Inc. (CIK: 0001816736) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IRON's EPS?
Disc Medicine, Inc. has a diluted EPS of $-1.65.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IRON a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Disc Medicine, Inc. has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IRON stock overvalued or undervalued?
Valuation metrics for IRON: ROE of -9.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IRON stock in 2026?
Our dual AI analysis gives Disc Medicine, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IRON's free cash flow?
Disc Medicine, Inc.'s operating cash flow is $-62.2M, with capital expenditures of $0.0.
How does IRON compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -9.2% (avg: 15%), current ratio 24.00 (avg: 2).